secwatch.observer — SEC 8-K summary
======================================

Issuer:     HARVARD BIOSCIENCE INC (HBIO)
CIK:        0001123494
Form:       8-K
Filed at:   2024-01-05T23:59:59+00:00
Accession:  0001171843-24-000099
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Harvard Bioscience prelim FY2023 revenue ~$112.3M; includes $5.1M discontinued product headwind
--------------------------------------------------------------------------------

- Preliminary unaudited FY2023 revenue estimate of ~$112.3M, down from $113.3M in FY2022, with $5.1M net headwind from discontinued products.
- Adjusted EBITDA for YTD Q3 2023 was $10.9M (13% of revenue), up 53% vs prior year; FY2022 adjusted EBITDA margin was 9.6%.
- Company cites Covid portfolio optimization and supply chain challenges as revenue headwinds.
- Guidance from Q3 2023 earnings (Nov 7, 2023) was for FY23 revenue down 11-14%; this presentation does not reaffirm guidance.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1123494/000117184324000099/0001171843-24-000099-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1123494/000117184324000099/f8k_010524.htm
  HTML page:      https://secwatch.observer/filing/0001171843-24-000099

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer